Location Columbus, Ohio, United States Regions Great Lakes, Midwestern US Gender Male
LinkedIn View on LinkedIn
Robert Shalwitz co-founded Akebia in 2007 and is continuing on as Chief Medical Officer at Aerpio. He has principal responsibility for the development of AKB-4924. During the last 5 years with Akebia, Robert Shalwitz brought AKB-6548 into Phase 2b for anemia. He was also very involved in the development of AKB-9778 for vascular leak, and bringing
in federal and state grants to support the wound healing program for AKB-4924.
Prior to Akebia, Robert Shalwitz was Vice President of Clinical Development at Reliant Pharmaceuticals, where he led a clinical team which launched and completed numerous clinical trials for the treatment of lipid and cardiac disorders, and contributed to several FDA filings.
Before Reliant, Robert Shalwitz was Medical Director at Abbott Labs. During his 10-year tenure at Abbott Labs, Robert Shalwitz team gained FDA approval for two NDAs (in lipid and cardiac disease). In addition, he acquired experience in all phases of drug development, from preclinical to Phase 4. Complementing his work in clinical development, Robert Shalwitz became very experienced in pharmaco-vigilance and post-marketing medical affairs.
Before Abbott Labs, Dr. Shalwitz was an academic pediatric endocrinologist for 10 years. His research at Washington University in St. Louis and at the Children's Hospital of Orange County (CA) focused on glucose and glycogen metabolism.
Dr. Shalwitz received an M.D. degree from SUNY Buffalo and a BGS degree from the University of Michigan.
